OBJECTIVES: Within the German hospital landscape (in-patient), NUBs (Neue Untersuchungs- und Behandlungsmethoden) [new treatment and examination methods] represent a key method to achieve reimbursement for new, cost-intensive drugs, medical products or procedures. NUBs are paid on top of hospital budget and hence represent additional funding for hospitals. The objective of this analysis was to provide an overview on the proportion of drugs (vs. methods, medicinal products) and their respective indications for 2015 and compare these to the results of 2014.  METHODS: The German DRG database issued by the InEK (Institute for Hospital Remuneration System) is used to analyse NUB subgroups sorted according to key therapeutic indications for the years 2015 and 2014. Additionally the number of NUB 1 (positive status) products that went through the AMNOG process up to June 2015 is being analysed.  RESULTS: Out of 670 NUB submissions 159 (24%) are classified as drugs in 2015. Results for the year 2014 were 618 NUB submissions with 133 (22%) drugs. The analysis also compares proportion of drugs in  different NUB classification levels for 2015 and 2014 (NUB 1-4). Leading therapeutic areas are identified. Chances to grant a successfull NUB 1 status approval for drugs and procedures are examined. Out of 56 drugs that were given NUB 1 status, 29 (52%) had passed through AMNOG process until June 2015. 43 drugs with NUB status 1 and 24 (55%) that had passed the early benefit assessment by June 2014 (55%).  CONCLUSIONS: Drug applications are more likely than procedures to be given NUB 1 status and thereby initiate reimbursement negotiations with the SHI. Results of 2015 confirm the findings for 2014. Oncology products showed the highest success rates in two consecutive years. Oncology products are often high priced therapies and use the NUB system to enter the G-DRG system for future reimbursement.